TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Market News Page 114 of 159 • 3,967 articles
3 Top Dividend Stocks to Buy in November
The Motley Fool • Reuben Gregg Brewer
3 Top Dividend Stocks to Buy in November

11/02/2025 07:32 PM • The article highlights three dividend stocks with strong track records: Chevron, Coca-Cola, and Realty Income. Each company offers attractive dividend yields and consistent dividend growth, making them appealing options for conservative income investors.

CVX - Impressive 38-year dividend increase streak, integrated business model, strong balance sheet, and above-market dividend yield of 4.4%
#dividend stocks #energy #consumer staples #real estate #income investing
Read More
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” Strategy
GlobeNewswire Inc. • Yt Jia
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” Strategy

11/02/2025 07:30 PM • Faraday Future announced strategic advisor Chris Nixon Cox, received B2B preorders for over 200 FX Super One units, and noted Vanguard increased its share holdings by 36% in Q3.

FFAI - Positive business developments including strategic advisor appointment, increased B2B preorders, and growing investor interest from Vanguard
#electric vehicle #EAI #crypto #Middle East expansion #B2B preorders
Read More
1 Vanguard Index Fund Heavy on
The Motley Fool • Stefon Walters
1 Vanguard Index Fund Heavy on "Magnificent Seven" Stocks Could Turn $500 per Month Into $800,000

11/02/2025 07:30 PM • The Vanguard S&P 500 ETF, heavily weighted towards the "Magnificent Seven" tech stocks, has historically averaged 12.8% annual returns and could potentially grow $500 monthly investments to $800,000 over time through compound earnings.

NVDA - Best performing Magnificent Seven stock, up over 1,380% in three years, world's most valuable public company due to AI boom
#Vanguard #S&P 500 #ETF #Magnificent Seven #tech stocks #investment #compound earnings
Read More
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
The Motley Fool • Reuben Gregg Brewer
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

11/02/2025 07:23 PM • The article highlights three growth stocks with potential long-term rewards: Intuitive Surgical (surgical robots), Dutch Bros (coffee chain), and Rivian (electric vehicles). Each company presents unique growth opportunities but comes with varying levels of investment risk.

ISRG - Well-established healthcare business with strong recurring revenue, growing installed base of surgical robots, and consistent expansion
#growth stocks #long-term investing #surgical robots #electric vehicles #coffee chain
Read More
The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)
The Motley Fool • Cory Renauer
The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)

11/02/2025 07:21 PM • Two international developed market ETFs, VEA and SPDW, offer similar performance and low costs, with VEA providing broader diversification through more holdings and a slightly higher dividend yield.

VEA - Offers broader diversification with 3,873 stocks, slightly higher dividend yield of 2.7%, and larger asset base of $250.8 billion
#ETF #international markets #diversification #investment #developed markets
Read More
Up 30% This Year and With Plenty of Room to Run, This Blue Chip Stock Is a Value Investor's Dream
The Motley Fool • Lee Samaha
Up 30% This Year and With Plenty of Room to Run, This Blue Chip Stock Is a Value Investor's Dream

11/02/2025 07:14 PM • 3M has seen significant operational improvements under new CEO Bill Brown, with a focus on innovation, operational efficiency, and restructuring. The company has increased new product introductions by 70% and improved equipment effectiveness, positioning itself for potential future growth.

MMM - Stock is up 30% year-to-date, management is implementing strategic improvements, increasing new product introductions, enhancing operational efficiency, and showing potential for future earnings growth
#value investing #operational improvements #new product innovation #industrial sector #restructuring
Read More
Tesla's Stock Just Got Riskier, but Is It Still a Buy?
The Motley Fool • Lee Samaha
Tesla's Stock Just Got Riskier, but Is It Still a Buy?

11/02/2025 07:05 PM • Tesla plans aggressive production expansion in 2026, betting heavily on robotaxis and unsupervised full self-driving technology, which increases stock risk but potentially offers higher rewards for investors.

TSLA - The stock is becoming a higher-risk/higher-reward proposition. While Elon Musk is confident about achieving unsupervised full self-driving technology, the aggressive expansion plans carry significant uncertainty and potential financial risks if the technology goals are not met.
#Tesla #robotaxis #full self-driving #EV production #Cybercab #autonomous driving
Read More
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
GlobeNewswire Inc. • Benitec Biopharma Inc.
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

11/02/2025 07:00 PM • Benitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.

GOOGL - Expected to report earnings of $2.32 per share on revenue of $99.64 billion, with a robust quality ranking
BNTC - Company is reporting ongoing clinical trial progress without indicating definitive positive or negative outcomes; presenting interim results of a Phase 1b/2a study
#gene therapy #clinical study #muscular dystrophy #RNA interference
Read More
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
GlobeNewswire Inc. • Hutchmed
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

11/02/2025 07:00 PM • HUTCHMED introduced its Antibody-Targeted Therapy Conjugate (ATTC) platform, focusing on a novel approach to cancer treatment using targeted therapies with dual mechanisms of action. The lead candidate HMPL-A251 demonstrates promising preclinical efficacy in targeting HER2-positive tumors with improved safety profiles.

HCM - Company showcased breakthrough research in cancer treatment with innovative ATTC platform, demonstrated promising preclinical results, and outlined clear development strategy for lead candidate HMPL-A251
#oncology #precision medicine #antibody-drug conjugates #cancer therapy #PI3K/PIKK inhibitor
Read More
ROSEN, INVESTOR RIGHTS COUNSEL, Encourages WPP plc Investors to Secure Deadline Before Important Deadline in Securities Class Action - WPP
GlobeNewswire Inc. • Rosen Law Firm
ROSEN, INVESTOR RIGHTS COUNSEL, Encourages WPP plc Investors to Secure Deadline Before Important Deadline in Securities Class Action - WPP

11/02/2025 06:59 PM • Rosen Law Firm is notifying WPP plc investors about a securities class action lawsuit alleging the company made false and misleading statements about its media arm's market performance during February 27 to July 8, 2025.

META - Expected to report earnings of $8.11 per share on revenue of $57.21 billion, with a poor value ranking
WPP - The lawsuit claims the company disseminated false statements about its media arm's performance, suggesting significant market share losses and inability to handle macroeconomic challenges, which indicates potential financial and operational difficulties
#securities #class action #investor rights #legal notice
Read More
SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA
GlobeNewswire Inc. • Rosen Law Firm
SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

11/02/2025 06:47 PM • Rosen Law Firm is alerting Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process.

MSFT - Expected to report earnings of $2.97 per share on revenue of $10.61 billion, with a strong growth ranking
SVRA - The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial's Biologics License Application, suggesting potential regulatory challenges and potential need for additional capital raising
#securities #class action #FDA #clinical trial #regulatory approval
Read More
FireFly appoints highly experienced resources specialist as Non-Executive Director
GlobeNewswire Inc. • Steve Parsons
FireFly appoints highly experienced resources specialist as Non-Executive Director

11/02/2025 06:30 PM • FireFly Metals Ltd has appointed Leanne Heywood, an experienced resources executive, as an Independent Non-Executive Director to strengthen its board's expertise in copper sector and financial management.

TER - Surged 20.91% after delivering better-than-expected Q3 earnings with a robust outlook
RIO - Mentioned as previous employer of the new director, with no direct impact on the company
#copper #mining #board appointment #resources executive #Green Bay Project
Read More
FMC Stock Is Crashing -- Here's Why
The Motley Fool • Ryan Vanzo
FMC Stock Is Crashing -- Here's Why

11/02/2025 06:23 PM • Agricultural sciences company FMC experienced a dramatic stock decline, losing nearly 90% of its value since 2023 due to poor financial performance, supply chain disruptions, and a significant dividend cut.

STX - Shares climbed 7.17% after beating earnings expectations on top and bottom lines
FMC - Company experienced massive stock price drop (40% in a week, 90% since 2023), reported significant financial losses ($569 million loss in recent quarter), reduced dividend, facing supply chain and international market challenges, and has negative free cash flow
#agricultural sciences #crop protection #stock decline #financial performance #supply chain
Read More
Could Robinhood Stock Be Worth $1 Trillion by 2030?
The Motley Fool • David Jagielski
Could Robinhood Stock Be Worth $1 Trillion by 2030?

11/02/2025 06:14 PM • Robinhood Markets has experienced significant growth, transforming from an unprofitable company to generating 40% profit margins. The stock has surged over 420% in the past year, with potential to reach a $1 trillion market cap by 2030, though market volatility and economic conditions could impact its trajectory.

HOOD - Strong financial performance, impressive growth trajectory, high retail investor interest, expanding into new markets like prediction markets, and potential for significant future valuation increase
#trading platform #retail investors #stock market #crypto trading #prediction markets
Read More
Is This Nevada-Based Company a Strong Play for Growth-Oriented Portfolios?
The Motley Fool • Steven Porrello
Is This Nevada-Based Company a Strong Play for Growth-Oriented Portfolios?

11/02/2025 06:05 PM • MP Materials, a rare earth metals mining company in California, has experienced significant stock volatility due to U.S.-China trade tensions. Despite recent price drops, the company has strategic partnerships with the Department of Defense and Apple, positioning itself as a critical supplier of rare earth metals for emerging technologies.

MP - The company shows potential with strategic partnerships and government investment, but is currently unprofitable and faces market uncertainty. Its long-term growth depends on successfully building manufacturing capacity and navigating geopolitical trade dynamics.
#rare earth metals #mining #electric vehicles #technology #strategic investment
Read More
Does Qualcomm's Entry Into the AI Chip Race Spell Trouble for Nvidia?
The Motley Fool • James Brumley
Does Qualcomm's Entry Into the AI Chip Race Spell Trouble for Nvidia?

11/02/2025 06:03 PM • Qualcomm announced its entry into the AI data center chip market with two new processors, challenging Nvidia's dominant market position and signaling increasing competition in the AI semiconductor industry.

CNM - Listed as a partner in Infinitii Ai's network without specific performance details
QCOM - Entering a new market with potential for growth, stock jumped 11% on announcement, and targeting a projected $60 billion data center chip market by 2034
#AI chips #data center processors #semiconductor market #technology competition
Read More
History Says the Nasdaq Will Surge in 2026. 1 Stock-Split Stock to Buy Before It Does.
The Motley Fool • Danny Vena
History Says the Nasdaq Will Surge in 2026. 1 Stock-Split Stock to Buy Before It Does.

11/02/2025 06:02 PM • Historical data suggests the Nasdaq will continue its bull market run into 2026, with Netflix positioned as a strong investment due to its robust content library, global expansion, and growing profitability in the streaming market.

NFLX - Strong revenue growth (17% increase), expanding global audience, successful original content, increasing operating margins, and positive analyst projections for continued growth in 2026
#Nasdaq #stock split #streaming #AI #bull market
Read More
LNTH DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – LNTH
GlobeNewswire Inc. • Rosen Law Firm
LNTH DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – LNTH

11/02/2025 05:27 PM • Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.

FLGpA - The bank is maintaining consistent dividend payments across multiple stock classes, indicating financial stability and commitment to shareholder returns
LNTH - The lawsuit alleges the company provided false and misleading statements about Pylarify's competitive position, failed to properly disclose pricing risks, and potentially misled investors about the product's growth potential
#securities class action #investor rights #Pylarify #price disclosure
Read More
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
GlobeNewswire Inc. • Benedikt Stefansson
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

11/02/2025 05:12 PM • Alvotech received a Complete Response Letter (CRL) from the FDA for its biosimilar candidate AVT05, requiring resolution of certain manufacturing facility deficiencies before approval. The company expects to address the issues and work with the FDA, but has lowered its 2025 revenue and EBITDA projections.

FLGpU - The bank is maintaining consistent dividend payments across multiple stock classes, indicating financial stability and commitment to shareholder returns
ALVO - Received FDA Complete Response Letter, lowered financial projections, and must resolve manufacturing facility issues before product approval
#biosimilar #FDA #CRL #manufacturing #golimumab
Read More
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum
GlobeNewswire Inc. • Benedikt Stefánsson
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum

11/02/2025 05:10 PM • Alvotech announced that the FDA will not approve its AVT05 biologics license application until manufacturing facility issues are resolved. The company expects lower 2025 revenues and will work to address FDA's concerns.

ALVO - FDA delayed markeT approval for AVT05, requiring manufacturing facility improvements, which will reduce projected 2025 revenues and temporarily slow production
#FDA #biologics #biosimilar #Simponi #manufacturing #license application
Read More
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
GlobeNewswire Inc. • Benedikt Stefansson
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

11/02/2025 05:10 PM • Alvotech received a Complete Response Letter from the FDA for its biosimilar candidate AVT05, requiring resolution of certain manufacturing facility deficiencies. The company expects to address the issues and work with the FDA to bring the product to market, but has lowered its 2025 revenue and EBITDA projections.

ALVO - Received FDA Complete Response Letter, lowered financial projections, and must resolve manufacturing facility issues which will temporarily slow production
#biosimilar #FDA #manufacturing #regulatory approval #golimumab
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
GlobeNewswire Inc. • Rosen Law Firm
ROSEN, LEADING INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

11/02/2025 04:38 PM • Rosen Law Firm filed a class action lawsuit against Avantor, alleging misrepresentation of competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.

HONDU - Served as merger partner in the transaction without significant additional context
AVTR - The lawsuit claims the company misrepresented its competitive positioning, experienced negative effects from increased competition, and made materially false statements about its business operations and prospects
#securities lawsuit #class action #investor rights #stock misrepresentation
Read More
Erie Indemnity (ERIE) Q3 2025 Earnings Transcript
The Motley Fool • Motley Fool Transcribing
Erie Indemnity (ERIE) Q3 2025 Earnings Transcript

11/02/2025 04:34 PM • Erie Indemnity reported Q3 2025 earnings with improved profitability metrics, facing challenges from severe weather events and increased claim severity. The company introduced a new auto insurance product and maintained a strong capital position despite a financial strength rating downgrade.

HONDW - Served as merger partner in the transaction without significant additional context
ERIE - Mixed performance with improved combined ratio and net income, but facing challenges from weather-related losses and rating downgrade. Proactively addressing profitability through rate adjustments and new product development.
#insurance #earnings #weather events #claim severity #profitability
Read More
Why BlackSky Technology Stock Plummeted This Week
The Motley Fool • Keith Noonan
Why BlackSky Technology Stock Plummeted This Week

11/02/2025 04:11 PM • BlackSky Technology's stock experienced a 10.7% decline this week due to shifting geopolitical dynamics, including U.S.-China trade negotiations and ongoing Russia-Ukraine conflict developments. Despite the pullback, the stock remains up 96% year-to-date.

BKSY - Stock experienced volatility due to geopolitical events, with a significant weekly decline but still maintaining strong year-to-date performance. The company's satellite intelligence services remain relevant in current global conflicts.
#geopolitical tensions #satellite intelligence #trade negotiations #Russia-Ukraine war
Read More
QUANTUM CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urges Quantum Stockholders to Contact the Firm Before November 3rd
GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
QUANTUM CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urges Quantum Stockholders to Contact the Firm Before November 3rd

11/02/2025 03:42 PM • A class action lawsuit has been filed against Quantum Corporation alleging improper revenue recognition and misleading financial statements during the period of November 15, 2024 to August 18, 2025.

PAVM - Parent company mentioned without specific performance details
QMCO - The lawsuit alleges the company improperly recognized revenue, will need to restate financial statements, and made materially false and misleading statements about its business, which suggests significant financial and legal challenges
#class action #securities #financial restatement #revenue recognition
Read More